Enanta Pharmaceuticals Inc (ENTA) insider trading
Every open-market stock purchase and sale by Enanta Pharmaceuticals Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders sold $183K over the last 12 months (9 sales). No open-market buys.
- Last insider buy: Jay R. Luly (CEO), $256K, 20 months ago.
Last 12 months: insiders bought $0 (0 buys) and sold $183K (9 sales). Last close $11.28 on Jun 4, 2026.
Recent ENTA insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Mar 11, 2026 | Terry Vance (Director) | Bought (not open market) | — |
| Mar 11, 2026 | Kristine Peterson (Director) | Bought (not open market) | — |
| Mar 11, 2026 | Bruce L A Carter (Director) | Bought (not open market) | — |
| Mar 11, 2026 | Yujiro S Hata (Director) | Bought (not open market) | — |
| Mar 11, 2026 | Mark G Foletta (Director) | Bought (not open market) | — |
| Mar 11, 2026 | Lesley Russell (Director) | Bought (not open market) | — |
| Feb 12, 2026 | Jay R. Luly (CEO) | Sold (not open market) | $87.7K |
| Feb 12, 2026 | Scott T. Rottinghaus (C-suite exec) | Sold (not open market) | $48.6K |
| Feb 12, 2026 | Yat Sun Or (C-suite exec) | Sold (not open market) | $48.6K |
| Feb 12, 2026 | Tara Lynn Kieffer (Officer) | Sold (not open market) | $46.4K |
| Feb 12, 2026 | Brendan Luu (C-suite exec) | Sold (not open market) | $46.4K |
| Feb 12, 2026 | Matthew Paul Kowalsky (C-suite exec) | Sold (not open market) | $27.1K |
| Feb 12, 2026 | Scott T. Rottinghaus (C-suite exec) | Bought (not open market) | — |
| Feb 12, 2026 | Matthew Paul Kowalsky (C-suite exec) | Bought (not open market) | — |
| Feb 12, 2026 | Jay R. Luly (CEO) | Bought (not open market) | — |
| Feb 12, 2026 | Tara Lynn Kieffer (Officer) | Bought (not open market) | — |
| Feb 12, 2026 | Matthew Paul Kowalsky (C-suite exec) | Bought (not open market) | — |
| Feb 12, 2026 | Yat Sun Or (C-suite exec) | Bought (not open market) | — |
| Feb 12, 2026 | Jay R. Luly (CEO) | Bought (not open market) | — |
| Feb 12, 2026 | Brendan Luu (C-suite exec) | Bought (not open market) | — |
| Feb 12, 2026 | Brendan Luu (C-suite exec) | Bought (not open market) | — |
| Feb 12, 2026 | Yat Sun Or (C-suite exec) | Bought (not open market) | — |
| Feb 12, 2026 | Scott T. Rottinghaus (C-suite exec) | Bought (not open market) | — |
| Feb 12, 2026 | Tara Lynn Kieffer (Officer) | Bought (not open market) | — |
| Dec 5, 2025 | Jay R. Luly (CEO) | Sold | $67.5K |
Who's trading ENTA
- Bruce L A Carter, Director: other filings, last Mar 11, 2026
- Mark G Foletta, Director: other filings, last Mar 11, 2026
- Yujiro S Hata, Director: other filings, last Mar 11, 2026
- Kristine Peterson, Director: other filings, last Mar 11, 2026
- Lesley Russell, Director: other filings, last Mar 11, 2026
- Terry Vance, Director: other filings, last Mar 11, 2026
- Matthew Paul Kowalsky, C-suite exec: other filings, last Feb 12, 2026
- Jay R. Luly, CEO: sold $67.5K (1 sale), last Feb 12, 2026
- Brendan Luu, C-suite exec: sold $19.8K (1 sale), last Feb 12, 2026
- Yat Sun Or, C-suite exec: sold $34K (1 sale), last Feb 12, 2026
- Scott T. Rottinghaus, C-suite exec: sold $11.4K (1 sale), last Feb 12, 2026
- Tara Lynn Kieffer, Officer: sold $30K (1 sale), last Feb 12, 2026
- Harry R. Trout III, Officer: sold $13K (2 sales), last Dec 5, 2025
- Kathleen S. Capps, Officer: sold $7.5K (2 sales), last Dec 5, 2025
Get free alerts when an insider at Enanta Pharmaceuticals Inc files a new trade →